Rani Therapeutics articles

San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results, as well as several corporate updates. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity, which opens doors for significant developments in biosimilars.  

Rani has been on the radar of major life science investors for years. The

(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract.

“This is not a new idea, although previous attempts were based on chemistry and about 99% of the drug was destroyed before it achieved any meaningful absorption,” Tala

Rani Therapeutics, a clinical-stage biotherapeutics company, based in San Jose, CA, is developing orally-administered biologics. Their novel, patented platform technology replaces subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible vehicle, approximately the size of a standard fish oil or calcium pill, which is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine . . .

Rani Therapeutics offers a breakthrough capsule, the RaniPill which could change the way patients with chronic conditions take medication by eliminating the need for painful injections.

Rani Therapeutics is a clinical-stage biotherapeutics company offering an alternative to painful injections for patients with chronic conditions such as

Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday. 

According to S-1 filings, shares were estimated to price between $14 and $16 last week. On Friday, shares debuted slightly lower, around $11. Rani raised about $73 million in its debut.

Rani’s debut comes amid